DURHAM, NC – Antiviral developer Chimerix says it has filed for an initial public offering.
Chimerix aims to raise up to $85 million in the offering. The company, which booked $34 million in revenue in 2012, plans to trade under the symbol CMRX on Nasdaq.
A registration statement has been filed but hasn’t become effective, the company says.
Morgan Stanley and Cowen and Company are acting as joint book-running managers, and William Blair and Lazard Capital Markets LLC are co-managers.
For more on how Chimerix is moving ahead with its antiviral candidates, click here.